Islet microencapsulation: strategies and clinical status in diabetes
M Omami, JJ McGarrigle, M Reedy, D Isa, S Ghani… - Current diabetes …, 2017 - Springer
Abstract Purpose of Review Type 1 diabetes mellitus (T1DM) is an autoimmune disease that
results from the destruction of insulin-producing pancreatic β cells in the islets of …
results from the destruction of insulin-producing pancreatic β cells in the islets of …
Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design
DM Sugrue, T Ward, S Rai, P McEwan… - …, 2019 - Springer
Background Chronic kidney disease (CKD) is a progressive condition that leads to
irreversible damage to the kidneys and is associated with an increased incidence of …
irreversible damage to the kidneys and is associated with an increased incidence of …
Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence
P McEwan, V Foos, B Martin, J Chen… - Diabetes, Obesity and …, 2023 - Wiley Online Library
Aims To comprehensively estimate the cost‐effectiveness of sodium glucose cotransporter‐
2 (SGLT2) inhibitor usage in the management of type 2 diabetes mellitus (T2DM) at …
2 (SGLT2) inhibitor usage in the management of type 2 diabetes mellitus (T2DM) at …
Artificial pancreas as an effective and safe alternative in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
X Dai, Z Luo, L Zhai, W Zhao, F Huang - Diabetes Therapy, 2018 - Springer
Introduction Insulin injection is the main treatment in patients with type 1 diabetes mellitus
(T1DM). Even though continuous glucose monitoring has significantly improved the …
(T1DM). Even though continuous glucose monitoring has significantly improved the …
Bringing stem cell‐based therapies for type 1 diabetes to the clinic: early insights from bioprocess economics and cost‐effectiveness analysis
C Bandeiras, JMS Cabral, RA Gabbay… - Biotechnology …, 2019 - Wiley Online Library
Differentiation of pluripotent stem cells (PSCs) into β cells could provide insulin
independence for type 1 diabetes (T1D) patients. This approach would reduce the clinical …
independence for type 1 diabetes (T1D) patients. This approach would reduce the clinical …
[HTML][HTML] Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping …
M Pesonen, V Jylhä, E Kankaanpää - JBI Evidence Synthesis, 2024 - journals.lww.com
Objective: The objective of this review was to examine the role of adverse drug events
(ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes …
(ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes …
Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA1c, weight and hypoglycaemic event incidence
P McEwan, H Bennett, K Bolin, M Evans… - Diabetic …, 2018 - Wiley Online Library
Aims Insulin therapy is indicated for people with Type 1 diabetes mellitus; however,
treatment‐related weight gain and hypoglycaemia represent barriers to optimal glycaemic …
treatment‐related weight gain and hypoglycaemia represent barriers to optimal glycaemic …
NICE guidance on dapagliflozin with insulin for type 1 diabetes
AI Adler, S Ting, R Dent, N Latimer - The Lancet Diabetes & …, 2019 - thelancet.com
On August 28, 2019, the National Institute for Health and Care Excellence (NICE) published
guidance recommending dapagliflozin (a sodium-glucose co-transporter-2 inhibitor) for …
guidance recommending dapagliflozin (a sodium-glucose co-transporter-2 inhibitor) for …
Cost‐effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom
H Bennett, A Tank, M Evans… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aims To assess the cost‐effectiveness of dapagliflozin, a sodium‐glucose co‐transporter‐2
(SGLT2) inhibitor, as an adjunct to insulin in adults with type 1 diabetes mellitus (T1DM) …
(SGLT2) inhibitor, as an adjunct to insulin in adults with type 1 diabetes mellitus (T1DM) …
A review of economic models submitted to NICE's technology appraisal programme, for treatments of T1DM & T2DM
MJ Daly, J Elvidge, T Chantler… - Frontiers in pharmacology, 2022 - frontiersin.org
Background: In the UK, 4.7 million people are currently living with diabetes. This is projected
to increase to 5 million by 2025. The direct and indirect costs of T1DM and T2DM are rising …
to increase to 5 million by 2025. The direct and indirect costs of T1DM and T2DM are rising …